Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: Clinical characteristics, risk factors, and subsequent therapy

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1549-1555

  Heng, D Y ^a   MacKenzie, M J ^b   Vaishampayan, U N ^c   Bjarnason, G A ^d   Knox, J J ^e   Tan, M H ^f   Wood, L ^g   Wang, Y ^a   Kollmannsberger, C ^h   North, S ⁱ   Donskov, F ^j   Rini, B I ^k   Choueiri, T K ^l  

^a UNIVERSITY OF CALGARY   (Canada)

^b Regional Health Sciences Center   (Canada)

^c KARMANOS CANCER INSTITUTE   (United States)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^g QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

^k TAUSSIG CANCER INSTITUTE   (United States)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

mTOR; Primary refractory; Renal cell carcinoma; VEGF

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADULT; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NEPHRECTOMY; NEUTROPHILIA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOSIS; TREATMENT RESPONSE;

EID: 84861735450     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr533     Document Type: Article

References (19)

1. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110: 543-550.
2. Heng DY, Chi KN, Murray N et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 2009; 115: 776-783.
3. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-5799.
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
5. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
6. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
7. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-2143.
8. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
9. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456.
10. Molina AM, Ginsberg MS, Motzer RJ. Long-term response with everolimus formetastatic renal cell carcinoma refractory to sunitinib. Med Oncol 2011 [epub ahead of print].
11. Vickers MM, Choueiri TK, Rogers M et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factortargeted therapy. Urology 2010.
12. Filson CP, Redman BG, Dunn RL, Miller DC. Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma. Urology 2011.
13. Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009; 182: 29-34; discussion 34.
14. Tamaskar I, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008; 179: 81-86.
15. Porta C, Procopio G, Carteni{dotless}' G et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int 2011 May 23 [epub ahead of print].
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
17. Grepin R, Pages G. Molecular mechanisms of resistance to tumour antiangiogenic strategies. J Oncol 2010; 2010: 835680.
18. Richey SL, Ng C, Lim ZD et al. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2010.
19. Rini BI, Escudier B, Tomczak P et al. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol 2011; 29 (Suppl) (Abstr 4503).